Actavis Up on Positive Phase III Ceftazidime-Avibactam Data - Analyst Blog

By
A A A

Actavis plc 's ( ACT ) shares were up 2.3% with the company announcing positive top-line results from the phase III RECLAIM-1 and -2 studies on ceftazidime-avibactam. Shares increased an additional 0.13% in the following trading session.

Ceftazidime/avibactam is being developed by Actavis in collaboration with AstraZeneca ( AZN ) for the treatment of adult hospitalized patients with serious gram-negative bacterial infections including complicated intra-abdominal infections (cIAI).

The randomized, multi-center, double-blind, double-dummy, parallel-group phase III studies evaluated the safety, efficacy and tolerability of ceftazidime-avibactam (administered intravenously as a two-hour infusion) plus metronidazole compared to meropenum (administered intravenously as a 30-minute infusion).

Actavis and AstraZeneca said that ceftazidime-avibactam achieved the primary endpoint - a clinical cure rate (28 to 35 days) after randomization. Results showed statistical non-inferiority compared to meropenum. Ceftazidime-avibactam was also found effective in treating cIAI patients infected with ceftazidime-resistant bacteria.

With the approval of the FDA and the European Medicines Agency, data from both studies were examined as a single-pooled dataset.

Ceftazidime-avibactam was granted qualified infectious disease product (QIDP) by the FDA in Sep 2013. The QIDP designation will provide priority review, eligibility for the FDA's fast track program, and a five-year extension of exclusivity under the Hatch-Waxman Act for the candidate.

We remind investors that ceftazidime/avibactam became a part of Actavis' portfolio through its recent acquisition of Forest Laboratories. While Forest Labs has commercialization rights in North America, rest of the world commercialization rights are with AstraZeneca.

Actavis is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Mallinckrodt plc ( MNK ) and Akorn, Inc. ( AKRX ). Both hold a Zacks Rank #1 (Strong Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

AKORN INC (AKRX): Free Stock Analysis Report

ACTAVIS PLC (ACT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AZN , MNK , AKRX , ACT

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

74,282,785
  • $10.84 ▲ 11.64%
60,794,128
  • $17.12 ▲ 0.71%
55,628,662
  • $35.59 ▼ 1.00%
55,306,290
  • $116.47 ▲ 0.14%
55,118,241
  • $39.75 ▼ 0.43%
53,597,648
  • $9.41 ▲ 8.29%
41,889,990
  • $47.98 ▼ 1.48%
35,692,375
  • $97.34 ▼ 0.57%
As of 11/21/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com